Drug Profile
Research programme: neurodegenerative disease therapeutics - Baylor College of Medicine/UCB
Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator Baylor College of Medicine; UCB
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Neurodegenerative-disorders in Belgium
- 28 Mar 2020 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 09 Feb 2016 UCB and Baylor College of Medicine agree to co-promote and co-develop Neurodegenerative disease therapeutics worldwide